These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
26. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents. Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973 [TBL] [Abstract][Full Text] [Related]
27. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Hafiane A; Daskalopoulou SS Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900 [TBL] [Abstract][Full Text] [Related]
28. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Bertrand MJ; Tardif JC Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063 [TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502 [TBL] [Abstract][Full Text] [Related]
30. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Ridker PM J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883 [TBL] [Abstract][Full Text] [Related]
31. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
32. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610 [TBL] [Abstract][Full Text] [Related]
34. Canakinumab for secondary prevention of coronary artery disease. Ortega-Paz L; Capodanno D; Angiolillo DJ Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289 [TBL] [Abstract][Full Text] [Related]
35. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ; Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124 [TBL] [Abstract][Full Text] [Related]
36. NLRP3 Inflammasome as a Common Denominator of Atherosclerosis and Abdominal Aortic Aneurysm. Takahashi M Circ J; 2021 Nov; 85(12):2129-2136. PubMed ID: 33883388 [TBL] [Abstract][Full Text] [Related]